US5962490A
(en)
*
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5846990A
(en)
*
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
TR200101905T2
(tr)
|
1997-04-28 |
2002-06-21 |
Texas Biotechnology Corporation |
Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
DE69830069T3
(de)
|
1997-10-17 |
2012-02-09 |
Ark Therapeutics Ltd. |
Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
|
CA2309588A1
(en)
*
|
1998-03-17 |
1999-09-23 |
Warner-Lambert Company |
Statin-matrix metalloproteinase inhibitor combinations
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
BR9911621A
(pt)
|
1998-07-06 |
2001-10-16 |
Bristol Myers Squibb Co |
Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
|
MY125533A
(en)
*
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
EP1741713A3
(en)
*
|
1999-12-15 |
2009-09-09 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
MXPA02006461A
(es)
|
1999-12-31 |
2003-09-05 |
Texas Biotechnology Corp |
Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US6639082B2
(en)
*
|
2000-10-17 |
2003-10-28 |
Bristol-Myers Squibb Company |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
WO2002049630A2
(en)
*
|
2000-12-21 |
2002-06-27 |
Bristol-Myers Squibb Company |
Method for preventing or treating pain by administering an endothelin antagonist
|
US20030040534A1
(en)
*
|
2001-04-16 |
2003-02-27 |
Hughes David E. |
Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide
|
CA2461202C
(en)
|
2001-09-21 |
2011-07-12 |
Donald Pinto |
Lactam-containing compounds and derivatives thereof as factor xa inhibitors
|
WO2003033671A2
(en)
*
|
2001-10-18 |
2003-04-24 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US8853266B2
(en)
*
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
TW200307539A
(en)
*
|
2002-02-01 |
2003-12-16 |
Bristol Myers Squibb Co |
Cycloalkyl inhibitors of potassium channel function
|
US7772433B2
(en)
*
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
TW200403058A
(en)
*
|
2002-04-19 |
2004-03-01 |
Bristol Myers Squibb Co |
Heterocyclo inhibitors of potassium channel function
|
US7435824B2
(en)
*
|
2002-04-19 |
2008-10-14 |
Bristol-Myers Squibb Company |
Prodrugs of potassium channel inhibitors
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
WO2003106628A2
(en)
*
|
2002-06-17 |
2003-12-24 |
Bristol-Myers Squibb Company |
Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
|
MY139563A
(en)
*
|
2002-09-04 |
2009-10-30 |
Bristol Myers Squibb Co |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US20040106663A1
(en)
*
|
2002-09-06 |
2004-06-03 |
Talley John Jeffrey |
Inhibitors of fungal invasion
|
ATE469645T1
(de)
*
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
WO2004045518A2
(en)
*
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
US8309603B2
(en)
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US20040176425A1
(en)
*
|
2003-01-24 |
2004-09-09 |
Washburn William N. |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
CL2004000545A1
(es)
*
|
2003-03-18 |
2005-01-28 |
Pharmacia Corp Sa Organizada B |
Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US6846836B2
(en)
*
|
2003-04-18 |
2005-01-25 |
Bristol-Myers Squibb Company |
N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7696241B2
(en)
*
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7772232B2
(en)
*
|
2004-04-15 |
2010-08-10 |
Bristol-Myers Squibb Company |
Quinazolinyl compounds as inhibitors of potassium channel function
|
US7550499B2
(en)
*
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
PL1750862T3
(pl)
*
|
2004-06-04 |
2011-06-30 |
Teva Pharma |
Kompozycja farmaceutyczna zawierająca irbesartan
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US7754755B2
(en)
*
|
2004-09-23 |
2010-07-13 |
Bristol-Myers Squibb Company |
Inhibitors of 15-lipoxygenase
|
US7429611B2
(en)
|
2004-09-23 |
2008-09-30 |
Bristol-Myers Squibb Company |
Indole inhibitors of 15-lipoxygenase
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US8143425B2
(en)
*
|
2004-10-12 |
2012-03-27 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US20060128726A1
(en)
*
|
2004-11-24 |
2006-06-15 |
Xuebao Wang |
Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076598A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076569A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7459564B2
(en)
|
2005-01-13 |
2008-12-02 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor XIa inhibitors
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7645778B2
(en)
*
|
2005-01-19 |
2010-01-12 |
Bristol-Myers Squibb Company |
Heteroaryl compounds as P2Y1 receptor inhibitors
|
WO2006086464A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
EP1879881A2
(en)
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
JP2008542292A
(ja)
*
|
2005-05-26 |
2008-11-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
N末端修飾glp−1受容体モジュレーター
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US7572808B2
(en)
*
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
DE602006020871D1
(de)
|
2005-06-27 |
2011-05-05 |
Bristol Myers Squibb Co |
Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
|
ES2352796T3
(es)
*
|
2005-06-27 |
2011-02-23 |
Bristol-Myers Squibb Company |
Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
|
AU2006261828A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
WO2007002634A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
EA200800430A1
(ru)
*
|
2005-07-28 |
2008-06-30 |
Бристол-Маерс Сквибб Компани |
Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
|
EP1757290A1
(en)
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
US7534804B2
(en)
*
|
2005-08-24 |
2009-05-19 |
Bristol-Myers Squibb Company |
Benzoxazole inhibitors of 15-lipoxygenase
|
WO2007027454A1
(en)
*
|
2005-08-30 |
2007-03-08 |
Bristol-Myers Squibb Company |
Heterocyclic dihydropyrimidine compounds
|
EP2425715B1
(en)
|
2005-08-31 |
2014-03-05 |
University of Tennessee Research Foundation |
Treating symptoms of renal disease with selective androgen receptor modulators (SARM)
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
EP2487154B1
(en)
|
2005-10-31 |
2013-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
JP2009523177A
(ja)
*
|
2006-01-11 |
2009-06-18 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒトグルカゴン様ペプチド−1調節因子、並びに糖尿病および関連症状の治療におけるその使用
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
RU2435585C2
(ru)
*
|
2006-04-13 |
2011-12-10 |
Актелион Фармасьютиклз Лтд |
Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
|
US20100022457A1
(en)
*
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
MX2009000385A
(es)
|
2006-07-12 |
2009-04-06 |
Univ Tennessee Res Foundation |
Acil-anilidas sustituidas y metodos de uso de las mismas.
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US10010521B2
(en)
|
2006-08-24 |
2018-07-03 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
ES2581765T3
(es)
|
2006-08-24 |
2016-09-07 |
University Of Tennessee Research Foundation |
Acilanilidas sustituidas y métodos de uso de las mismas
|
US7960569B2
(en)
*
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
CA2676066C
(en)
|
2007-01-22 |
2016-06-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US9604931B2
(en)
|
2007-01-22 |
2017-03-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US9623021B2
(en)
*
|
2007-01-22 |
2017-04-18 |
Gtx, Inc. |
Nuclear receptor binding agents
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
EP2142551B1
(en)
|
2007-04-17 |
2015-10-14 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
MX2009011089A
(es)
*
|
2007-04-23 |
2009-10-30 |
Sanofi Aventis |
Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
|
WO2008137435A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Bristol-Myers Squibb Company |
[6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
|
US8093257B2
(en)
*
|
2007-05-04 |
2012-01-10 |
Bristol-Myers Squibb Company |
[6,5]-bicyclic GPR119 G protein-coupled receptor agonists
|
WO2008144346A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Bristol-Myers Squibb Company |
Crystal structures of sglt2 inhibitors and processes for their preparation
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
TW200904440A
(en)
*
|
2007-07-17 |
2009-02-01 |
Bristol Myers Squibb Co |
Method for modulating GPR119 G protein-coupled receptor and selected compounds
|
ES2408384T3
(es)
*
|
2007-07-27 |
2013-06-20 |
Bristol-Myers Squibb Company |
Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
EP2238128B1
(en)
*
|
2007-12-26 |
2012-08-22 |
Sanofi |
Heterocyclic pyrazole-carboxamides as p2y12 antagonists
|
AR070176A1
(es)
|
2008-01-17 |
2010-03-17 |
Novartis Ag |
Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
|
EP2103602A1
(en)
|
2008-03-17 |
2009-09-23 |
AEterna Zentaris GmbH |
Novel 1,2,4-triazole derivatives and process of manufacturing thereof
|
CL2009001214A1
(es)
|
2008-05-19 |
2010-12-31 |
Schering Corp |
Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
TW201006821A
(en)
|
2008-07-16 |
2010-02-16 |
Bristol Myers Squibb Co |
Pyridone and pyridazone analogues as GPR119 modulators
|
JP2012522015A
(ja)
|
2009-03-27 |
2012-09-20 |
ブリストル−マイヤーズ スクイブ カンパニー |
Dpp−iv阻害剤を用いて主要有害心血管事象を予防する方法
|
JP5775071B2
(ja)
|
2009-06-16 |
2015-09-09 |
ファイザー・インク |
アピキサバンの製剤形
|
EP2462123B1
(en)
|
2009-08-04 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
ES2689107T3
(es)
|
2009-11-13 |
2018-11-08 |
Astrazeneca Ab |
Formulaciones de tabletas bicapa
|
CA2780941C
(en)
|
2009-11-13 |
2018-06-12 |
Bristol-Myers Squibb Company |
Immediate release tablet formulations
|
JP5798123B2
(ja)
|
2009-11-13 |
2015-10-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低質量のメトホルミン製剤
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011127106A1
(en)
|
2010-04-08 |
2011-10-13 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
|
US8592396B2
(en)
|
2010-04-14 |
2013-11-26 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
CN102971311B
(zh)
|
2010-05-06 |
2015-07-08 |
百时美施贵宝公司 |
作为gpr119调节剂的二环杂芳基化合物
|
EP2566862B1
(en)
|
2010-05-06 |
2015-09-16 |
Bristol-Myers Squibb Company |
Benzofuranyl analogues as gpr119 modulators
|
PL2609075T3
(pl)
|
2010-08-23 |
2016-09-30 |
|
Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP
|
EP2431035A1
(en)
|
2010-09-16 |
2012-03-21 |
Æterna Zentaris GmbH |
Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US9233073B2
(en)
|
2010-12-23 |
2016-01-12 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
UA108713C2
(xx)
|
2011-11-11 |
2015-05-25 |
|
2-тіопіримідинони
|
CN104334557A
(zh)
|
2012-04-06 |
2015-02-04 |
辉瑞公司 |
二酰基甘油酰基转移酶2抑制剂
|
EP2850073B1
(en)
|
2012-05-16 |
2017-07-19 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
|
ES2675314T3
(es)
|
2012-06-11 |
2018-07-10 |
Bristol-Myers Squibb Company |
Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino) quinazolin-2-il] piridin-3-sulfonamida
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
PT2872482T
(pt)
|
2012-07-13 |
2020-09-22 |
Oncternal Therapeutics Inc |
Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US9586900B2
(en)
|
2012-09-05 |
2017-03-07 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
WO2014039412A1
(en)
|
2012-09-05 |
2014-03-13 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
CN105025895B
(zh)
|
2012-11-14 |
2019-02-26 |
比亚尔-波特拉&Ca有限公司 |
用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物
|
PT2925735T
(pt)
|
2012-11-20 |
2019-06-04 |
Lexicon Pharmaceuticals Inc |
Inibidores do cotransportador de sódio e glucose 1
|
JP6386527B2
(ja)
|
2013-03-11 |
2018-09-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
カリウムイオンチャネル阻害剤としてのピロロピリダジン
|
WO2014143609A1
(en)
|
2013-03-11 |
2014-09-18 |
Bristol-Myers Squibb Company |
Isoquinolines as potassium ion channel inhibitors
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
CN105026399B
(zh)
|
2013-03-11 |
2017-06-23 |
百时美施贵宝公司 |
作为钾离子通道抑制剂的吡咯并三嗪类化合物
|
US9242966B2
(en)
|
2013-03-11 |
2016-01-26 |
Bristol-Myers Squibb Company |
Phthalazines as potassium ion channel inhibitors
|
JP6348582B2
(ja)
|
2013-10-09 |
2018-06-27 |
ファイザー・インク |
プロスタグランジンep3受容体の拮抗薬
|
WO2015061272A1
(en)
|
2013-10-22 |
2015-04-30 |
Bristol-Myers Squibb Company |
Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
|
MX2016012008A
(es)
|
2014-03-17 |
2016-12-07 |
Pfizer |
Inhibidores de diacilglicerol acil transferasa 2 para utilizarlos en el tratamiento de enfermedades metabolicas y relacionadas.
|
HUE057876T2
(hu)
|
2014-04-04 |
2022-06-28 |
Pfizer |
Biciklusos-kondenzált heteroaril- vagy aril-vegyületek és ezek IRAK4 inhibitorként történõ alkalmazása
|
EP3131897B8
(en)
|
2014-04-16 |
2022-08-03 |
Merck Sharp & Dohme LLC |
Factor ixa inhibitors
|
BR112016027778A2
(pt)
|
2014-05-30 |
2017-08-15 |
Pfizer |
Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
|
JP2017538769A
(ja)
|
2014-12-22 |
2017-12-28 |
ファイザー・インク |
プロスタグランジンep3受容体の拮抗薬
|
SG11201708407TA
(en)
|
2015-05-05 |
2017-11-29 |
Pfizer |
2-thiopyrimidinones
|
JP2018516254A
(ja)
|
2015-05-29 |
2018-06-21 |
ファイザー・インク |
バニン1酵素の阻害薬としての新規なヘテロ環化合物
|
WO2016203347A1
(en)
|
2015-06-17 |
2016-12-22 |
Pfizer Inc. |
Tricyclic compounds and their use as phosphodiesterase inhibitors
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
CA2995153A1
(en)
|
2015-08-13 |
2017-02-16 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds
|
CA2996389C
(en)
|
2015-08-27 |
2020-04-07 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
|
WO2017037567A1
(en)
|
2015-09-03 |
2017-03-09 |
Pfizer Inc. |
Regulators of frataxin
|
SG11201804363UA
(en)
|
2015-12-29 |
2018-07-30 |
Pfizer |
Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
|
CA3030381A1
(en)
|
2016-07-14 |
2018-01-18 |
Pfizer Inc. |
Pyrimidine carboxamides as inhibitors of vanin-1 enzyme
|
WO2018017910A1
(en)
|
2016-07-22 |
2018-01-25 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
EP3716979A1
(en)
|
2017-11-30 |
2020-10-07 |
Idorsia Pharmaceuticals Ltd |
Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
|
WO2019133445A1
(en)
|
2017-12-28 |
2019-07-04 |
Inception Ibd, Inc. |
Aminothiazoles as inhibitors of vanin-1
|
SG11202100417RA
(en)
|
2018-07-19 |
2021-02-25 |
Astrazeneca Ab |
Methods of treating hfpef employing dapagliflozin and compositions comprising the same
|
JP7161605B2
(ja)
|
2018-08-31 |
2022-10-26 |
ファイザー・インク |
Nash/nafldおよび関連疾患の治療のための組合せ
|
EP3856714A1
(en)
|
2018-09-26 |
2021-08-04 |
Lexicon Pharmaceuticals, Inc. |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
WO2020102575A1
(en)
|
2018-11-16 |
2020-05-22 |
Inception Ibd, Inc. |
Heterocyclic aminothiazoles and uses thereof
|
WO2020234726A1
(en)
|
2019-05-20 |
2020-11-26 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
JP7498199B2
(ja)
|
2019-06-28 |
2024-06-11 |
ファイザー・インク |
種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
IL292350A
(en)
|
2019-10-30 |
2022-06-01 |
Perfuse Therapeutics Inc |
Treatment of ocular diseases using endothelin receptor antagonists
|
EP4100406A4
(en)
*
|
2020-02-06 |
2023-07-05 |
Perfuse Therapeutics, Inc. |
COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
CN116113635A
(zh)
|
2020-06-09 |
2023-05-12 |
辉瑞公司 |
作为黑皮质素4受体拮抗剂的螺环化合物及其用途
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
JP2024515826A
(ja)
*
|
2021-04-30 |
2024-04-10 |
パフューズ セラピューティクス, インコーポレイテッド |
眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム
|
KR20240022646A
(ko)
|
2021-06-22 |
2024-02-20 |
앨커메디신, 인크. |
화합물, 엔도텔린 a 수용체 길항제 및 의약 조성물
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023026180A1
(en)
|
2021-08-26 |
2023-03-02 |
Pfizer Inc. |
Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
|
CA3240990A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
CN118510504A
(zh)
|
2022-01-26 |
2024-08-16 |
阿斯利康(瑞典)有限公司 |
用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
WO2024125602A1
(en)
|
2022-12-15 |
2024-06-20 |
Gasherbrum Bio, Inc. |
Salts and solid forms of a compound having glp-1 agonist activity
|
WO2024127297A1
(en)
|
2022-12-16 |
2024-06-20 |
Pfizer Inc. |
3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
|